Beijing Tong Ren Tang Chinese Medicine (SEHK:3613) - Hisse Senedi Fiyatı, Haberler ve Analizler

3613 Stoklara Genel Bakış

3613 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	1/6
Finansal Sağlık	5/6
Temettüler	4/6

Ödüller

Adil değer tahminimizden 21.3% daha düşük bir oranda işlem görüyor

Kazançların yılda 16.51% oranında artması öngörülüyor

Risk Analizi

Yüksek düzeyde nakit olmayan kazançlar

4.17% temettüsü serbest nakit akışları tarafından iyi karşılanmıyor

Beijing Tong Ren Tang Chinese Medicine Company Limited Rakipler

Tong Ren Tang Technologies

SEHK:1666

HK$6.4b

Consun Pharmaceutical Group

SEHK:1681

HK$6.6b

China Shineway Pharmaceutical Group

SEHK:2877

HK$6.7b

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd

SEHK:1349

HK$7.2b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Beijing Tong Ren Tang Chinese Medicine
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	HK$7.91
52 Haftanın En Yüksek Seviyesi	HK$13.44
52 Haftanın En Düşük Seviyesi	HK$7.03
Beta	0.47
11 Aylık Değişim	-4.58%
3 Aylık Değişim	-5.61%
1 Yıllık Değişim	-39.43%
33 Yıllık Değişim	-24.23%
5 Yıllık Değişim	-23.35%
Halka arzdan bu yana değişim	21.13%

Son Haberler & Güncellemeler

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Shares Climb 32% But Its Business Is Yet to Catch Up

Oct 04

Earnings Troubles May Signal Larger Issues for Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Shareholders

Sep 06

Recent updates

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Shares Climb 32% But Its Business Is Yet to Catch Up

Oct 04

Earnings Troubles May Signal Larger Issues for Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Shareholders

Sep 06

Is There An Opportunity With Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 31% Undervaluation?

Sep 02

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk

Feb 05

Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Jan 03

A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Sep 28

Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today

Jul 12

Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?

Mar 29

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28

Apr 28

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28

Mar 25

Are Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Investors Paying Above The Intrinsic Value?

Oct 27

Beijing Tong Ren Tang Chinese Medicine's (HKG:3613) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 28

Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

Mar 11

What Type Of Returns Would Beijing Tong Ren Tang Chinese Medicine's(HKG:3613) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Feb 04

Should Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Be Part Of Your Dividend Portfolio?

Jan 18

Could The Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Ownership Structure Tell Us Something Useful?

Dec 29

Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

Dec 11

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Nov 23

Hissedar Getirileri

	3613	HK Pharmaceuticals	HK Pazar
7D	-2.7%	0.3%	-2.8%
1Y	-39.4%	-12.3%	10.0%

Getiri vs. Endüstri: 3613 geçen yıl % -12.3 oranında getiri sağlayan Hong Kong Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: 3613 geçen yıl % 10 oranında getiri sağlayan Hong Kong Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 3613's price volatile compared to industry and market?
3613 volatility
3613 Average Weekly Movement	6.7%
Pharmaceuticals Industry Average Movement	6.7%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	19.0%
10% least volatile stocks in HK Market	4.2%

İstikrarlı Hisse Senedi Fiyatı: 3613 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 3613 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1669	779	Wang Chi	www.tongrentangcm.com

Beijing Tong Ren Tang Chinese Medicine Company Limited, iştirakleriyle birlikte, toptancılara ve bireylere sağlık ürünleri ve Çin tıbbı üretimi, perakende satışı ve toptan satışı yapmaktadır. Şirket üç segmentte faaliyet göstermektedir: Hong Kong, Çin Anakarası ve Denizaşırı. Ayrıca Çin tıbbi danışmanlık ve tedavi hizmetleri de sunmaktadır.

Beijing Tong Ren Tang Chinese Medicine Company Limited Temel Bilgiler Özeti

Beijing Tong Ren Tang Chinese Medicine'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
3613 temel i̇stati̇sti̇kler
Piyasa değeri	HK$6.62b
Kazançlar(TTM)	HK$494.14m
Gelir(TTM)	HK$1.38b

13.4x

F/K Oranı

4.8x

P/S Oranı

3613 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
3613 gelir tablosu (TTM)
Gelir	HK$1.38b
Gelir Maliyeti	HK$384.69m
Brüt Kâr	HK$991.96m
Diğer Giderler	HK$497.83m
Kazançlar	HK$494.14m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.59
Brüt Marj	72.06%
Net Kâr Marjı	35.89%
Borç/Özkaynak Oranı	0.006%

3613 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

4.2%

Mevcut Temettü Verimi

56%

Ödeme Oranı

3613 Stoklara Genel Bakış

Ödüller

Risk Analizi

Beijing Tong Ren Tang Chinese Medicine Company Limited Rakipler

SEHK:1666

HK$6.4b

SEHK:1681

HK$6.6b

SEHK:2877

HK$6.7b

SEHK:1349

HK$7.2b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Shares Climb 32% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 22%

Earnings Troubles May Signal Larger Issues for Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Shareholders

First half 2024 earnings released: EPS: HK$0.26 (vs HK$0.32 in 1H 2023)

Recent updates

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Shares Climb 32% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 22%

Earnings Troubles May Signal Larger Issues for Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Shareholders

First half 2024 earnings released: EPS: HK$0.26 (vs HK$0.32 in 1H 2023)

Is There An Opportunity With Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 31% Undervaluation?

New major risk - Earnings quality

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2024 Results on Aug 30, 2024

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended December 31, 2023

Now 22% overvalued after recent price rise

Upcoming dividend of HK$0.33 per share

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Wang Chi as an Executive Director and a Member of the Competition Executive Committee

Now 21% overvalued after recent price rise

Full year 2023 earnings: EPS and revenues miss analyst expectations

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces CEO Changes

Beijing Tong Ren Tang Chinese Medicine Company Limited, Annual General Meeting, May 31, 2024

New minor risk - Financial data availability

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk

Price target decreased by 14% to HK$14.93

Investor sentiment deteriorates as stock falls 16%

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Fiscal Year 2023 Results on Mar 31, 2024

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Gu Hai Ou as Executive Director, Chairman of Board and Authorised Representative

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Nine Months, 2023 Results on Oct 31, 2023

A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Resignation of Lin Man as Executive Director, Chief Operating Officer, Member of Competition Executive Committee

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Retirement of Ding Yong Ling as Executive Director and Chairman of the Board

First half 2023 earnings released: EPS: HK$0.32 (vs HK$0.26 in 1H 2022)

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2023 Results on Aug 10, 2023

Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.33 per share at 2.1% yield

Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?

Price target increased by 8.0% to HK$14.66

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Nine Months, 2022 Results on Oct 31, 2022

Upcoming dividend of HK$0.25 per share

Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Special Interim Dividend, Payable on 21 October 2022

High number of new directors

COO & Executive Director recently bought HK$183k worth of stock

Price target decreased to HK$13.57

First half 2022 earnings released

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Feng Li as Executive Director

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2022 Results on Aug 12, 2022

Investor sentiment improved over the past week

Upcoming dividend of HK$0.28 per share

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Final Dividend for the Year Ended 31 December 2021

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Fiscal Year 2021 Results on Mar 07, 2022

Investor sentiment improved over the past week

CEO & Executive Director recently bought HK$178k worth of stock